2025
Diagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments
Travers S, Alexandre J, Baldassarre L, Salem J, Mirabel M. Diagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments. Archives Of Cardiovascular Diseases 2025, 118: 185-198. PMID: 39947997, DOI: 10.1016/j.acvd.2024.12.012.Peer-Reviewed Original ResearchConceptsCardio-oncologyCardiovascular toxicityCardiovascular imagingMultimodality cardiovascular imagingCancer risk factorsIncrease diagnostic accuracyPrognostic stratificationNatriuretic peptideSerum biomarkersTherapy schemesDiagnostic accuracyCancer therapyRhythm disordersRisk factorsCardiovascular diseaseBiomarkersMultimodal integrated approachCancerOmics approachesToxicityRhythmTherapyTroponinSerumDiagnosisHow to Use Imaging: Complex Cases of Atherosclerosis, Myocardial Inflammation, and Cardiomyopathy in Cardio-Oncology
Khattab M, Baig M, Zarif T, Barac A, Ferencik M, Henry M, Lopez-Mattei J, Redheuil A, Salem J, Scherrer-Crosbie M, Yang E, Baldassarre L. How to Use Imaging: Complex Cases of Atherosclerosis, Myocardial Inflammation, and Cardiomyopathy in Cardio-Oncology. Circulation Cardiovascular Imaging 2025, 18: e015981. PMID: 39772610, DOI: 10.1161/circimaging.124.015981.Peer-Reviewed Original ResearchConceptsCardio-oncologyCases of atherosclerosisCardiac magnetic resonance imagingCoronary computed tomography angiographySingle-photon emission computed tomographyImmune checkpoint inhibitorsLeft ventricular dysfunctionMultimodality cardiac imagingTyrosine kinase inhibitorsCardiac imaging modalitiesComputed tomography angiographyRisk of cardiovascular diseaseEmission computed tomographyPositron emission tomographyMagnetic resonance imagingCheckpoint inhibitorsVentricular dysfunctionMyocardial inflammationCoronary vasospasmAccelerated atherosclerosisKinase inhibitorsPatient populationDiagnosing such pathologiesCancer therapyCardiac imaging
2024
Gastrointestinal Cancer Therapy and Cardiotoxicity
Leiva O, Zarif T, Alvarez-Cardona J. Gastrointestinal Cancer Therapy and Cardiotoxicity. Current Treatment Options In Oncology 2024, 25: 1203-1209. PMID: 39102169, DOI: 10.1007/s11864-024-01236-x.Peer-Reviewed Original ResearchConceptsTyrosine kinase inhibitorsGastrointestinal cancerAnti-vascular endothelial growth factorHeterogeneous group of cancersCancer-specific outcomesEndothelial growth factorGroup of cancersConventional chemotherapyCardiotoxic therapiesTargeted therapyPotential cardiotoxicityKinase inhibitorsRisk factorsCardiovascular diseaseGrowth factorCancerHeterogeneous groupTherapyCardiotoxicityImmunotherapyChemotherapyPatientsLate Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children
Lo A, Liu A, Liu Q, Yasui Y, Castellino S, Kelly K, Hererra A, Friedberg J, Friedman D, Schwartz C, Pei Q, Kessel S, Bergeron-Gravel S, Dama H, Roberts K, Constine L, Hodgson D. Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children. JAMA Network Open 2024, 7: e2351062. PMID: 38241048, PMCID: PMC10799264, DOI: 10.1001/jamanetworkopen.2023.51062.Peer-Reviewed Original ResearchConceptsCardiac toxic effectsMediastinal RTHodgkin lymphomaRadiation therapyCumulative incidenceCardiac diseaseDoxorubicin doseCohort studyClinical trialsMedian mean heart doseChildren's Oncology Group clinical trialStudy populationHigh-risk HLMean heart dosePlanned cumulative doseRadiation therapy useIncidence of cardiac diseaseCumulative doxorubicin doseRisks associated with treatmentNorth American trialsGroup clinical trialFollow-up guidelinesStandard treatment groupToxic effectsMaintained long term
2023
Cooperative sensing of mitochondrial DNA by ZBP1 and cGAS promotes cardiotoxicity
Lei Y, VanPortfliet J, Chen Y, Bryant J, Li Y, Fails D, Torres-Odio S, Ragan K, Deng J, Mohan A, Wang B, Brahms O, Yates S, Spencer M, Tong C, Bosenberg M, West L, Shadel G, Shutt T, Upton J, Li P, West A. Cooperative sensing of mitochondrial DNA by ZBP1 and cGAS promotes cardiotoxicity. Cell 2023, 186: 3013-3032.e22. PMID: 37352855, PMCID: PMC10330843, DOI: 10.1016/j.cell.2023.05.039.Peer-Reviewed Original ResearchQuantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients
Kwan J, Arbune A, Henry M, Hu R, Wei W, Nguyen V, Lee S, Lopez-Mattei J, Guha A, Huber S, Bader A, Meadows J, Sinusas A, Mojibian H, Peters D, Lustberg M, Hull S, Baldassarre L. Quantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients. PLOS ONE 2023, 18: e0286364. PMID: 37252927, PMCID: PMC10228774, DOI: 10.1371/journal.pone.0286364.Peer-Reviewed Original ResearchConceptsBreast cancer patientsSystolic heart failureCardiovascular outcomesCancer patientsHeart failureValvular diseaseStrain abnormalitiesLeft ventricular ejection fraction reductionCancer treatment-related cardiotoxicityCardiovascular magnetic resonance findingsVentricular ejection fraction reductionYale-New Haven HospitalEjection fraction reductionTreatment-related cardiotoxicityAdverse cardiovascular outcomesClinical risk factorsNormal LV functionGlobal longitudinal strainIschemic heart diseaseMagnetic resonance findingsRisk regression modelsNew Haven HospitalSubclinical cardiotoxicityDiastolic dysfunctionStatin use
2022
Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy 3-Year Results of the SUCCOUR Trial
Negishi T, Thavendiranathan P, Penicka M, Lemieux J, Murbraech K, Miyazaki S, Shirazi M, Santoro C, Cho G, Popescu B, Kosmala W, Costello B, la Gerche A, Mottram P, Thomas L, Seldrum S, Hristova K, Bansal M, Kurosawa K, Fukuda N, Yamada H, Izumo M, Tajiri K, Sinski M, Vinereanu D, Shkolnik E, Banchs J, Kutty S, Negishi K, Marwick T. Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy 3-Year Results of the SUCCOUR Trial. JACC Cardiovascular Imaging 2022, 16: 269-278. PMID: 36435732, DOI: 10.1016/j.jcmg.2022.10.010.Peer-Reviewed Original ResearchConceptsGlobal longitudinal strainCancer therapeutics-related cardiac dysfunctionCardiac dysfunctionCardiotoxic chemotherapyHeart failureMulticenter prospective randomized controlled trialPatients treated with anthracyclinesProspective randomized controlled trialsBaseline to 3 yearsLeft ventricular functionRandomized controlled trialsChemotherapy regimenLV dysfunctionVentricular functionBreast cancerFollow-upDiabetes mellitusChemotherapyLongitudinal strainPatientsRisk factorsCardioprotectionDysfunctionCancerAnthracyclinesPET imaging of mitochondrial function in acute doxorubicin-induced cardiotoxicity: a proof-of-principle study
Detmer F, Alpert N, Moon S, Dhaynaut M, Guerrero J, Guehl N, Xing F, Brugarolas P, Shoup T, Normandin M, Pelletier-Galarneau M, El Fakhri G, Petibon Y. PET imaging of mitochondrial function in acute doxorubicin-induced cardiotoxicity: a proof-of-principle study. Scientific Reports 2022, 12: 6122. PMID: 35414642, PMCID: PMC9005533, DOI: 10.1038/s41598-022-10004-6.Peer-Reviewed Original ResearchConceptsLeft anterior descending coronary arteryDoxorubicin-induced cardiotoxicityCardiac membrane potentialDoxorubicin infusionMembrane potentialAnimal modelsAcute doxorubicin-induced cardiotoxicityLeft anterior descending coronary artery territoryAcute cardiotoxic effectsAnterior descending coronary arteryControl saline infusionDescending coronary arteryDoxorubicin doseSaline infusionTest infusionCardiotoxic effectsMitochondrial membrane potentialInfusion catheterCoronary arteryInfusionMitochondrial functionDoxorubicinMyocardial areaPET imagingIntracoronary catheter
2021
Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience
Batra A, Patel B, Addison D, Baldassarre LA, Desai N, Weintraub N, Deswal A, Hussain Z, Brown SA, Ganatra S, Agarwala V, Parikh PM, Fradley M, Ghosh A, Guha A. Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. Open Heart 2021, 8: e001849. PMID: 34952868, PMCID: PMC8710909, DOI: 10.1136/openhrt-2021-001849.Peer-Reviewed Original ResearchConceptsCardiovascular adverse eventsAdverse Event Reporting SystemCombination therapyAntimicrotubular agentsVinca alkaloidsAdverse eventsDrug Administration Adverse Event Reporting SystemRoutine cardiovascular assessmentCardiovascular safety profilePolytomous logistic regressionEvent Reporting SystemAgent therapyCombination chemotherapyHeart failureRegistry experienceSafety profileCardiovascular assessmentHigh burdenInhibitor combinationsChemotherapeutic agentsTaxanesTherapyLogistic regressionMonotherapyReporting systemModeling Precision Cardio-Oncology: Using Human-Induced Pluripotent Stem Cells for Risk Stratification and Prevention
Perry T, Roberts M, Sunkara B, Maddula R, McLeish T, Gomez J, Lucas J, Rayan D, Patel S, Liang M, Bosnjak Z, Brown S. Modeling Precision Cardio-Oncology: Using Human-Induced Pluripotent Stem Cells for Risk Stratification and Prevention. Current Oncology Reports 2021, 23: 77. PMID: 33937943, PMCID: PMC8088904, DOI: 10.1007/s11912-021-01066-2.Peer-Reviewed Original ResearchConceptsHuman induced pluripotent stem cellsHuman induced pluripotent stem cell modelsTyrosine kinase inhibitorsCardiovascular toxicityBody mass indexCardio-oncologyPluripotent stem cellsManagement of cardiovascular toxicityMechanisms of cardiovascular toxicityMultidisciplinary team of cardiologistsCancer therapyRisk factorsStem cellsCardiovascular diseaseHuman epidermal growth factor receptorManagement of modifiable risk factorsPatient-specific cardiomyocytesEpidermal growth factor receptorPatient-specific treatment plansTeam of cardiologistsGrowth factor receptorCardiovascular risk factorsModifiable risk factorsCancer therapeutic agentsReduce cardiovascular diseaseLeft ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity
Higgins AY, Arbune A, Soufer A, Ragheb E, Kwan JM, Lamy J, Henry M, Cuomo JR, Charifa A, Gallegos C, Hull S, Coviello JS, Bader AS, Peters DC, Huber S, Mojibian HR, Sinusas AJ, Kluger H, Baldassarre LA. Left ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity. PLOS ONE 2021, 16: e0246764. PMID: 33606757, PMCID: PMC7895343, DOI: 10.1371/journal.pone.0246764.Peer-Reviewed Original ResearchConceptsGlobal longitudinal strainImmune checkpoint inhibitorsLate gadolinium enhancementRecovery of LVEFLake Louise criteriaCheckpoint inhibitorsNormal LVEFAverage global longitudinal strainPresence of LGEAbnormal global longitudinal strainCardiac magnetic resonance imagingCorrect clinical contextEvaluation of myocarditisLeft ventricular dysfunctionVentricular ejection fractionDiagnosis of myocarditisLeft ventricular strainCardiac magnetic resonanceLeft ventricular myocardial strainOvert left ventricular dysfunctionVentricular myocardial strainMagnetic resonance imagingAtrial strainVentricular dysfunctionVentricular strain
2020
Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils
Baldassarre LA, Yang EH, Cheng RK, DeCara JM, Dent S, Liu JE, Rudski LG, Strom JB, Thavendiranathan P, Barac A, Zaha VG, Bucciarelli-Ducci C, Ellahham S, Deswal A, Lenneman C, Villarraga HR, Blaes AH, Ismail-Khan R, Ky B, Leja MJ, Scherrer-Crosbie M. Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging Councils. Journal Of The National Cancer Institute 2020, 113: 513-522. PMID: 33179744, PMCID: PMC7717327, DOI: 10.1093/jnci/djaa177.Peer-Reviewed Original ResearchMeSH KeywordsCardiotoxicityCardiovascular DiseasesCOVID-19Diagnostic ImagingExpert TestimonyHumansNeoplasmsSARS-CoV-2ConceptsCardio-OncologyCardiovascular careCOVID-19Cardio-oncology patientsPrior cancer historyExpert consensus statementCoronavirus disease 2019 (COVID-19) pandemicExpert consensus documentRisk of infectionDisease 2019 pandemicCardiotoxicity surveillanceCardiovascular complicationsPericardial involvementLethal complicationCardiac dysfunctionOncology patientsRisk of exposureCancer historyCancer patientsCardiovascular diseaseConsensus statementAmerican CollegeCardiovascular treatmentConsensus documentPatientsTemporal Trends in Arrhythmogenicity Related to Treatment of COVID-19 Infection
Hummel JP, Maraj I, Taoutel R, Chamoun R, Workman VK, Tran L, Abboud JM, Afif C, Chouairi S, Delvecchio A, Howes CJ, Enriquez AD, Akar JG. Temporal Trends in Arrhythmogenicity Related to Treatment of COVID-19 Infection. Circulation Arrhythmia And Electrophysiology 2020, 13: e008841-e008841. PMID: 32931318, PMCID: PMC7566294, DOI: 10.1161/circep.120.008841.Peer-Reviewed Original ResearchElectrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation
Friedman DM, Kim M, Costedoat-Chalumeau N, Clancy R, Copel J, Phoon CK, Cuneo B, Cohen R, Masson M, Wainwright BJ, Zahr N, Saxena A, Izmirly P, Buyon JP. Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation. Circulation Arrhythmia And Electrophysiology 2020, 13: e008686. PMID: 32907357, PMCID: PMC7668319, DOI: 10.1161/circep.120.008686.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsCardiotoxicityDrug Administration ScheduleDrug MonitoringElectrocardiographyFemaleFetal BloodFetal HeartGestational AgeHeart BlockHeart RateHumansHydroxychloroquineInfantInfant, NewbornMalePredictive Value of TestsPregnancyRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeConceptsBlood levelsSSA/Ro antibodiesHistorical healthy controlsHydroxychloroquine blood levelsCord blood levelsCongenital heart blockSystemic lupus erythematosusTrimester of pregnancyEfficacy of hydroxychloroquineCoronavirus disease-19Electrocardiographic QT intervalCOVID-19 studiesPostnatal ECGRo antibodiesIndividual pregnanciesLupus erythematosusQTc prolongationAntiviral therapyHeart blockClinical efficacyRheumatic conditionsDrug exposureMaternal useCord bloodDisease-19A pilot study of 13N-ammonia cardiac PET imaging to assess subacute cardiotoxicity following adjuvant intensity-modulated radiotherapy for locally advanced breast cancer
Nehmeh S, Fox J, Schwartz J, Ballangrud Å, Schöder H, Zhao Y, Strauss H, Yu A, Gupta D, Powell S, Ho A. A pilot study of 13N-ammonia cardiac PET imaging to assess subacute cardiotoxicity following adjuvant intensity-modulated radiotherapy for locally advanced breast cancer. Clinical Imaging 2020, 68: 283-290. PMID: 32919154, PMCID: PMC8207896, DOI: 10.1016/j.clinimag.2020.07.026.Peer-Reviewed Original ResearchConceptsRate-pressure productMyocardial flow reserveLABC patientsChest wallMyocardial segmentsAdjuvant intensity-modulated radiotherapyCardiac PET imagingPET imagingRadiotherapy treatment positionAdvanced breast cancerRegional lymph nodesBreast cancer patientsTreatment positionIntensity-modulated radiotherapySubacute cardiotoxicityHeart doseRT doseBlood pressureLymph nodesCoronary territoriesBC patientsCancer patientsCardiac functionBreast cancerFlow reserveOpportunities for improved cardiovascular disease prevention in oncology patients.
Bravo-Jaimes K, Marcellon R, Varanitskaya L, Kim PY, Iliescu C, Gilchrist SC, Baldassarre LA, Manisty C, Ghosh AK, Guha A, Lopez-Mattei JC. Opportunities for improved cardiovascular disease prevention in oncology patients. Current Opinion In Cardiology 2020, 35: 531-537. PMID: 32649353, DOI: 10.1097/hco.0000000000000767.Peer-Reviewed Original ResearchConceptsCardiovascular disease preventionCancer patientsDisease preventionCardiovascular disease prevention guidelinesCardiac risk factor modificationCancer treatmentCardiometabolic disease managementDisease prevention guidelinesCardiovascular risk factorsHigh cardiovascular riskRisk factor modificationAdverse cardiovascular outcomesRisk of cardiotoxicityOngoing clinical trialsNonpharmacologic therapiesCardiovascular eventsCardiovascular outcomesCardiovascular riskOncology patientsCancer survivorsPrevention guidelinesAdverse outcomesFactor modificationCardiorespiratory fitnessRisk factorsMolecular imaging to guide precision diagnosis and prevention of cancer therapeutics-related cardiac dysfunction
Oikonomou EK. Molecular imaging to guide precision diagnosis and prevention of cancer therapeutics-related cardiac dysfunction. Expert Review Of Molecular Diagnostics 2020, 20: 355-358. PMID: 31944137, DOI: 10.1080/14737159.2020.1717336.Commentaries, Editorials and LettersCardiotoxicity in Hematopoietic Stem Cell Transplant: Keeping the Beat
Baker JK, Shank-Coviello J, Zhou B, Dixon J, McCorkle R, Sarpong D, Medoff E, Cooper D, Seropian S, Dai F. Cardiotoxicity in Hematopoietic Stem Cell Transplant: Keeping the Beat. Clinical Lymphoma Myeloma & Leukemia 2020, 20: 244-251.e4. PMID: 32067953, DOI: 10.1016/j.clml.2019.12.027.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantCardiac eventsStem cell transplantCell transplantAtrial arrhythmiasAcute heart failureInstances of bradycardiaNew-onset hypertensionAcute coronary syndromeCoronary artery diseaseRisk of deathMultivariable regression analysisCoronary syndromeOnset hypertensionHSCT populationArtery diseaseHeart failureHSCT outcomesPericardial effusionAtrial dilationVentricular arrhythmiasSingle institutionSubgroup analysisBody of evidenceMedical history
2019
Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity
Oikonomou EK, Kokkinidis DG, Kampaktsis PN, Amir EA, Marwick TH, Gupta D, Thavendiranathan P. Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity. JAMA Cardiology 2019, 4: 1007-1018. PMID: 31433450, PMCID: PMC6705141, DOI: 10.1001/jamacardio.2019.2952.Peer-Reviewed Original ResearchConceptsCancer therapy-related cardiac dysfunctionGlobal longitudinal strainLeft ventricular global longitudinal strainVentricular global longitudinal strainPrognostic valueCutoff valuePublication biasMeasurement of GLSNew-onset heart failure symptomsAbsolute global longitudinal strainWorse global longitudinal strainLarge prospective multicenter studyLeft ventricular ejection fractionDiscriminatory performanceLongitudinal strainChemotherapy-Induced CardiotoxicityGLS cutoff valueSubclinical ventricular dysfunctionHeart failure symptomsProspective multicenter studyVentricular ejection fractionCochrane Library databasesRisk of biasOptimal cutoff valueBetter prognostic performanceDoxorubicin-Induced Cardiotoxicity in Collaborative Cross (CC) Mice Recapitulates Individual Cardiotoxicity in Humans
Zeiss CJ, Gatti DM, Toro-Salazar O, Davis C, Lutz CM, Spinale F, Stearns T, Furtado MB, Churchill GA. Doxorubicin-Induced Cardiotoxicity in Collaborative Cross (CC) Mice Recapitulates Individual Cardiotoxicity in Humans. G3: Genes, Genomes, Genetics 2019, 9: 2637-2646. PMID: 31263061, PMCID: PMC6686936, DOI: 10.1534/g3.119.400232.Peer-Reviewed Original ResearchConceptsCardiac diseaseCardiac pathologyCardiac troponin I levelsUltimate severityChronic cardiac injuryTroponin I levelsPotential predictive biomarkersDoxorubicin-Induced CardiotoxicityComplete blood countPanel of biomarkersCurrent mouse modelsEffect of treatmentCardiac troponin IProgressive cardiotoxicityLight chain 3Acute periodAcute phaseCardiac injuryRenal toxicityBlood countPredictive biomarkersChronic timepointsCollaborative Cross miceSame doseI levels
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply